Market Overview

Ebola Stocks Continue Higher

Share:
Related BCRX
US Stock Futures Rise Ahead Of Economic Data
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema

With over 700 already dead, the worst Ebola outbreak in history is pressuring the demand for development of new drugs to fight the Ebola virus.

On Friday, The U.S. Food and Drug Administration said the agency stands ready to work with companies to develop drugs for patients "in dire need of treatment."

Some of the companies that are likely to benefit include Tekmira Pharmaceuticals (NASDAQ: TKMR), Nano Vircides (NASDAQ: NNVC) and BioCryst Pharamceuticals (NASDAQ: BCRX).

Shares of all three companies were trading higher on the open, with TKMR up nearly 15 percent at $16.50.

Posted-In: EbolaNews Global Movers

 

Related Articles (BCRX + NNVC)

Around the Web, We're Loving...

Get Benzinga's Newsletters